Sellas Life Sciences jumps on positive results for its combination breast cancer therapy

10:12 EDT 1 Jun 2018 | Proactive Investors

The clinical trial for the biotech’s NeuVax and Herceptin combination therapy was terminated early thanks to quick positive results

More From BioPortfolio on "Sellas Life Sciences jumps on positive results for its combination breast cancer therapy"